Our company has obtained a Japanese invention patent for "Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method," with certificate number Patent No. 7514898.
Today (29th), Origin BioMedicals (6483) debuted on the Emerging Stock Market at a reference price of NT$20 per share, focusing on the development of multiple 505(b)(2) new drugs. These include OBM-B01 for the prevention and treatment of cyanide poisoning from fire inhalation, as well as OBM-A01 for the prevention and treatment of radiation injuries.
